Mary Kerr

Operating Partner

Mary Kerr joined Advent Life Sciences as Operating Partner and Chief Executive Officer (CEO) of NeRRe Therapeutics, an Advent Portfolio company in 2015. In 2017 Mary co-founded and was CEO of KaNDy Therapeutics, a spin-out and sister company to NeRRe. KaNDy was acquired by Bayer in September 2020 for an upfront consideration of $425m and potential deal value >$1b. Mary is a non-executive independent director at Galapagos NV. Before her career in Biotech, Mary held a range of senior leadership roles at GlaxoSmithKline and heritage companies for more than 20 years, including Senior Vice President and Global Franchise leader for the Immuno-inflammation and Infectious Diseases franchise. Mary was a founding member and on the Corporate Executive team of ViiV Healthcare and lead the European business. She has spent most of her career on the R&D commercial interface in global strategy and regional operational roles, predominantly in the specialty and orphan space. Mary gained a BSc and Ph.D. in Pharmacology at the University of Bradford, did post-doctoral research at the Michigan Cancer Foundation in Detroit, and has an MBA from the University of Kingston.

Assistant: Christopher James
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
T: +44 (0)20 7932 2157